VIATRIS INC. Net Income (Loss) Available to Common Stockholders, Basic
VIATRIS INC. (VTRS) reported Net Income (Loss) Available to Common Stockholders, Basic of -$118.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- VIATRIS INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$118.80M.
- VIATRIS INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $176.40M.
- VIATRIS INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$128.20M, a 235.23% decline year-over-year.
- VIATRIS INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$4.60M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month |
|---|---|---|---|
| 2026-06-30 | -$118.80M 10-Q · filed 2026-08-06 | $57.60M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $176.40M 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | -$128.20M 10-Q · filed 2025-11-06 | -$132.80M derived: sum of 2 quarters · filed 2026-08-06 | -$3.17B 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$4.60M 10-Q · filed 2026-08-06 | -$3.05B 10-Q · filed 2026-08-06 | |
| 2025-03-31 | -$3.04B 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $94.80M 10-Q · filed 2025-11-06 | -$231.60M derived: sum of 2 quarters · filed 2025-11-06 | -$117.70M 10-Q · filed 2025-11-06 |
| 2024-06-30 | -$326.40M 10-Q · filed 2025-08-07 | -$212.50M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $113.90M 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $331.60M 10-Q · filed 2024-11-07 | $595.60M derived: sum of 2 quarters · filed 2024-11-07 | $820.30M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $264.00M 10-Q · filed 2024-08-08 | $488.70M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $224.70M 10-Q · filed 2024-05-09 | ||
| 2022-09-30 | $354.30M 10-Q · filed 2023-11-08 | $668.20M derived: sum of 2 quarters · filed 2023-11-08 | $1.07B 10-Q · filed 2023-11-08 |
| 2022-06-30 | $313.90M 10-Q · filed 2023-08-07 | $713.10M 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $399.20M 10-Q · filed 2023-05-08 | ||
| 2021-09-30 | $311.50M 10-Q · filed 2022-11-07 | $32.30M derived: sum of 2 quarters · filed 2022-11-07 | -$1.01B 10-Q · filed 2022-11-07 |
| 2021-06-30 | -$279.20M 10-Q · filed 2022-08-08 | -$1.32B 10-Q · filed 2022-08-08 | |
| 2021-03-31 | -$1.04B 10-Q · filed 2022-05-09 | ||
| 2020-09-30 | $185.70M 10-Q · filed 2021-11-08 | $225.10M derived: sum of 2 quarters · filed 2021-11-08 | $245.90M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $39.40M 10-Q · filed 2021-08-09 | $60.20M 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $20.80M 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |